Allergan makes device acquisition amid Pfizer M&A rumors; Feds release study of FDA's postmarket surveillance;

@FierceMedDev: Roche launches rapid HIV, hep C tests in Europe. Article | Follow @FierceMedDev

@VarunSaxena2: Medtronic releases health economics study of its drug-coated balloon at Las Vegas conference. Story | Follow @VarunSaxena2

@EmilyWFierce: Does AstraZeneca own the color purple? On a pill, yes, the company contends. FiercePharmaMarketing story | Follow @EmilyWFierce

> Allergan ($AGN) announced the acquisition of Northwood Medical Innovation, maker of the earFold device to correct prominent ears, with or without asymmetry, in patients 7 and over. The company is currently being pursued by Pfizer ($PFE). A deal to acquire the company would be largest M&A transaction of the year. More

> The Government Accountability Office released a study on the FDA's postmarket studies of devices. It comes as the FDA is putting increasing emphasis on postmarket surveillance to ensure safety and possibly enable short premarket review times. More

Biotech News

@FierceBiotech: Biogen spells out its moonshot R&D strategy amid deep cost cuts. More | Follow @FierceBiotech

@JohnCFierce: Oxford team spotlights promise of AstraZeneca drug in targeting cancers. FierceBiotechResearch article | Follow @JohnCFierce

> Flagship launches another microbiome biotech with $35M and a focus on cancer. Report

> Allergan bets $50M on a dry eye drug as it touts its commitment to R&D. Story

> Vertex looks to gene therapy, RNA deals to quash takeover talk. Article

Pharma News

@FiercePharma: GSK's vaccine unit sees revenue, profit jump in Q3. More from FierceVaccines | Follow @FiercePharma

@CarlyHFierce: Good thing Bayer's in Germany, CEO says. U.S. business culture is too impatient. Story | Follow @CarlyHFierce

> McCaskill turns up heat on Valeant with Senate pricing probe. Story

> Novo adding 450 more Denmark jobs as its bets on growth in insulin demand. Article

Pharma Marketing News

> GlaxoSmithKline's HIV bright spot could get brighter with new Tivicay combo meds. Item

> Viewers skeptical of DTC ads, but they drive people to docs anyway. More

> Bristol-Myers Q3 ad spending pushes up to $193M on renewed promotions push. Story

> Pfizer launches first Prevnar TV spot to bring in the 50-plus crowd. Report

> Does AstraZeneca own the color purple? On a pill, yes, the company contends. Article

Biotech Research News

> Neat 'trick' guards peptides against early degradation. Story

> JAK inhibitors target senescent cells in aging study. Item

> Small molecule used to blunt glioblastoma growth in mice--UCSD. More

> Researchers devise heat-triggered liposome 'grenades' to destroy cancer cells. Story

> UPenn researchers show importance of calcium signaling for Ebola virus. Article

Vaccines News

> Takeda, Hilleman eye low-cost vaccine space. News

> Sanofi expects first dengue vaccine license in Q4. Item

> Pfizer teams up with the Biovac Institute to produce Prevenar 13 in South Africa. Report

> GSK's vaccine unit sees revenue, profit jump in Q3. Story

> European Commission launches €23M HIV vaccine research initiative. Article

Suggested Articles

The two companies also plan to identify new potential targets and therapeutic candidates for inflammatory bowel disease, or IBD.

This would allow centralized, lab-based diagnostic hardware to process blood samples at scale, screening patients for previous infections.

GlaxoSmithKline and AstraZeneca are considering forming a joint lab to help the U.K. expand its supplies for COVID-19 testing, according to Bloomberg.